Related Experiment Video
Updated: Jun 7, 2026

Ex Vivo Release of Calcitonin Gene-Related Peptide from the Trigeminovascular System in Rodents
Published on: May 16, 2022
CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine
J F Tvedskov1, P Tfelt-Hansen, K A Petersen
1Department of Neurology, Danish Headache Center, Denmark. tvedskov@dadlnet.dk
Unlabelled:
There is a striking similarity between the migraine-provoking effect of the nitric oxide (NO) donor glyceryl trinitrate (GTN) and that of calcitonin gene-related peptide (CGRP). We tested the hypothesis that NO releases CGRP to cause the delayed migraine attack after GTN.
Methods:
In a double-blind-cross-over study, 13 migraine without aura (MO) patients were administered GTN 0.5 µg/kg/minute for 20 minutes and subsequently BIBN4096BS (olcegepant) 10 mg or placebo. Headache scores and development of MO were followed for 24 hours.
Results:
MO developed in seven of 13 with olcegepant and in nine of 13 with placebo (p=0.68). The headache scores were similar after the two treatments (p=0.58). Thus CGRP receptor blockade did not prevent GTN-induced migraine.
Conclusions:
The present study indicates that NO does not induce migraine by liberating CGRP. The most likely explanation for our findings is that CGRP has its effect higher than NO in the cascade of events leading to MO attacks.
Related Concept Videos
Drugs Acting on Autonomic Ganglia: Blockers
GPCRs Regulate Adenylyl Cylase Activity
Two...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
GPCR Desensitization
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

